ABRT:CC - Albert Labs Eyes 1 Dose Psilocybin Treatment for Cancer-related Anxiety

2023-04-25 16:00:00 ET

Albert Labs (CSE:ABRT) is gearing up for the first in-human study of its primary drug target, KRN 101, designed as a one dose treatment for cancer-related anxiety and depression, according to CEO and Chairman Dr. Michael Raymont.

The company is wrapping up its animal testing phase and will soon move toward in-human study, said Raymont. In November 2022, Albert Labs signed a letter of intent with iNGEN? to carry out the company’s first in-human study, which will take place in Melbourne, Australia.

“Our clinical trial plan focuses on cancer-related distress, because it's very simple: If you receive a diagnosis of cancer, and you're distressed by that, then you go through the treatment, which is one 25 milligram dose, and associated psychotherapy, and then three months later, (patients are asked), ‘Are you free of that anxiety?’ And if more than even 50 percent of the patients are free of that anxiety, then the regulator has a very easy choice to make,” Raymont said.

For further details see: